|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Macular opacity | 06.09.03.021 | 0.017426% | | Not Available |
| Malignant melanoma in situ | 23.08.01.004; 16.03.01.004 | 0.014521% | | Not Available |
| Metastases to lymph nodes | 16.22.02.006; 01.09.01.015 | 0.014521% | | Not Available |
| Osteitis deformans | 15.02.04.013 | 0.005809% | | Not Available |
| Persecutory delusion | 19.10.01.007 | 0.011617% | | Not Available |
| Toxic optic neuropathy | 12.03.01.033; 06.02.08.003; 17.04.05.009 | 0.078415% | | Not Available |
| Urinary bladder rupture | 20.03.01.024; 12.01.05.007 | 0.020330% | | Not Available |
| Corneal bleeding | 24.07.05.012; 06.07.01.005 | 0.011617% | | Not Available |
| Pulmonary cavitation | 22.01.02.022 | 0.005809% | | Not Available |
| Cell death | 14.11.02.005; 08.03.03.003 | 0.017426% | | Not Available |
| Subacute cutaneous lupus erythematosus | 23.03.02.020; 15.06.02.012; 10.04.03.012 | 0.011617% | | Not Available |
| Acute myeloid leukaemia recurrent | 16.01.05.004; 01.10.05.004 | 0.005809% | | Not Available |
| Leukaemia recurrent | 16.01.03.005; 01.10.03.005 | 0.014521% | | Not Available |
| Metastatic squamous cell carcinoma | 16.16.01.010 | 0.011617% | | Not Available |
| Acute lymphocytic leukaemia recurrent | 16.01.01.003; 01.10.01.003 | 0.005809% | | Not Available |
| Mucosal necrosis | 08.01.06.023 | 0.008713% | | Not Available |
| Graft versus host disease in gastrointestinal tract | 12.02.09.028; 10.02.01.059; 07.11.01.027 | 0.005809% | | Not Available |
| Disorganised speech | 19.19.02.005; 17.02.08.017 | 0.029043% | | Not Available |
| Anembryonic gestation | 18.01.03.007 | - | - | Not Available |
| Dilated cardiomyopathy | 02.04.01.017 | 0.020330% | | Not Available |
| Drug ineffective for unapproved indication | 12.09.02.002; 08.06.01.038 | 0.074349% | | Not Available |
| Dyschromatopsia | 06.02.09.003 | 0.069121% | | Not Available |
| Fixed eruption | 23.03.05.008; 10.01.01.037; 08.01.06.025 | - | - | Not Available |
| Haemophagocytic lymphohistiocytosis | 01.05.01.026; 16.32.03.038; 10.02.01.077 | 0.005809% | | Not Available |
| Hepatic cytolysis | 09.01.07.036 | 0.055181% | | Not Available |
| Inhibitory drug interaction | 08.06.03.014 | 0.011617% | | Not Available |
| Intermenstrual bleeding | 21.01.01.015 | - | - | Not Available |
| Lung opacity | 22.12.01.006 | 0.008713% | | Not Available |
| Mucosal disorder | 08.01.06.029 | - | - | Not Available |
| Muscle oedema | 15.05.03.038; 12.01.07.017 | 0.012779% | | Not Available |
